Literature DB >> 26450194

CANCER. The odds of immunotherapy success.

Matthew M Gubin1, Robert D Schreiber2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26450194     DOI： 10.1126/science.aad4140

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  33 in total

1.  B-cell acute lymphoblastic leukemia with high mutation burden presenting in a child with constitutional mismatch repair deficiency.

Authors:  Benjamin Oshrine; Nanette Grana; Colin Moore; Johnny Nguyen; Melissa Crenshaw; Melissa Edwards; Sumedha Sudhaman; Victoria J Forster; Uri Tabori
Journal:  Blood Adv       Date:  2019-06-25

2.  Protein Footprinting and X-ray Crystallography Reveal the Interaction of PD-L1 and a Macrocyclic Peptide.

Authors:  Ben Niu; Todd C Appleby; Ruth Wang; Mariya Morar; Johannes Voight; Armando G Villaseñor; Sheila Clancy; Sarah Wise; Jean-Philippe Belzile; Giuseppe Papalia; Melanie Wong; Katherine M Brendza; Latesh Lad; Michael L Gross
Journal:  Biochemistry       Date:  2019-12-31       Impact factor: 3.162

3.  Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma.

Authors:  Motao Zhu; Xilai Ding; Ruifang Zhao; Xuewu Liu; Haifa Shen; Chunmei Cai; Mauro Ferrari; Helen Y Wang; Rong-Fu Wang
Journal:  J Control Release       Date:  2018-01-08       Impact factor: 9.776

Review 4.  Preclinical and clinical development of neoantigen vaccines.

Authors:  L Li; S P Goedegebuure; W E Gillanders
Journal:  Ann Oncol       Date:  2017-12-01       Impact factor: 32.976

5.  Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience.

Authors:  Susan Chi; Kee Kiat Yeo; Chantel Cacciotti; Jungwhan Choi; Sanda Alexandrescu; Mary Ann Zimmerman; Tabitha M Cooney; Christine Chordas; Jessica Clymer
Journal:  J Neurooncol       Date:  2020-07-05       Impact factor: 4.130

Review 6.  Multimodality Therapy of Patients with Refractory Meningiomas.

Authors:  Haroon Ahmad; David Schiff
Journal:  Curr Treat Options Oncol       Date:  2019-05-09

Review 7.  Melanoma: What do all the mutations mean?

Authors:  Elizabeth J Davis; Douglas B Johnson; Jeffrey A Sosman; Sunandana Chandra
Journal:  Cancer       Date:  2018-04-17       Impact factor: 6.860

8.  Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.

Authors:  Ludmila Danilova; Hao Wang; Joel Sunshine; Genevieve J Kaunitz; Tricia R Cottrell; Haiying Xu; Jessica Esandrio; Robert A Anders; Leslie Cope; Drew M Pardoll; Charles G Drake; Janis M Taube
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-11       Impact factor: 11.205

Review 9.  Neoantigen-based cancer immunotherapy.

Authors:  Sara Bobisse; Periklis G Foukas; George Coukos; Alexandre Harari
Journal:  Ann Transl Med       Date:  2016-07

10.  Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.

Authors:  Douglas B Johnson; Garrett M Frampton; Matthew J Rioth; Erik Yusko; Yaomin Xu; Xingyi Guo; Riley C Ennis; David Fabrizio; Zachary R Chalmers; Joel Greenbowe; Siraj M Ali; Sohail Balasubramanian; James X Sun; Yuting He; Dennie T Frederick; Igor Puzanov; Justin M Balko; Justin M Cates; Jeffrey S Ross; Catherine Sanders; Harlan Robins; Yu Shyr; Vincent A Miller; Philip J Stephens; Ryan J Sullivan; Jeffrey A Sosman; Christine M Lovly
Journal:  Cancer Immunol Res       Date:  2016-09-26       Impact factor: 11.151
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.